October
2004 | Vol. 8, No. 1
1 AMA PRA Category 1 Credit
Antibodies Targeting the Epidermal Growth Factor Receptor in Non–Small-Cell Lung Cancer
Table of Contents
Recent Data With Cetuximab in Advanced Non–Small-Cell Lung Cancer
Edward S. Kim, MD
The Fully Human, Anti–Epidermal Growth Factor Receptor Antibody Panitumumab (ABX-EGF) Combined With Paclitaxel/Carboplatin for Advanced Non–Small-Cell Lung Cancer
Jeffrey Crawford, MD
Alan B. Sandler, MD
Early Clinical Trials With Matuzumab (EMD 72000), a Humanized Anti–Epidermal Growth Factor Receptor Antibody, in Non–Small-Cell Lung Cancer
Rajesh K. Malik, MB, ChB
Learning Objectives | Back to top
Upon completion of this learning material, physicians should be able to:
- Describe the activity of the anti–epidermal growth factor receptor antibody cetuximab as a single agent and in combination with chemotherapy in NSCLC
- Discuss the safety of combining monoclonal antibodies targeting the epidermal growth factor receptor with chemotherapy in NSCLC
- Compare and contrast chimeric humanized and fully human
antibodies against the epidermal growth factor receptor
Activity Goals | Back to top
Lung cancer remains the single greatest cause of cancer-related mortality in the United States. According to the American Cancer Society, 173,770 people will be diagnosed in 2004, with approximately 160,000 resultant deaths. As many as 75%-85% of patients will be diagnosed with non–small-cell lung cancer (NSCLC), and almost 80% of these will have advanced disease at diagnosis. Chemotherapy is the standard of care for advanced NSCLC; however, treatment remains suboptimal, with median survival times of < 1 year for these patients. Investigative approaches, focused on improving current treatment standards, include integration of novel agents, novel schedules for existing regimens, and more aggressive intervention with chemotherapy at earlier stages of disease. Monoclonal antibodies such as cetuximab, matuzumab, and panitumumab that bind to the extracellular domain of the epidermal growth factor receptor (EGFR) seem to be promising.
The purpose of this activity is to educate physicians on the recent advances in the use of EGFR-targeted agents in advanced NSCLC.
Target Audience | Back to top
This publication is intended for medical oncologists involved in the care of patients with lung cancer. No specific skills or knowledge other than a basic training in oncology are required for successful participation in this activity.
Accreditation | Back to top
Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource designates this educational activity for a maximum of 1 category 1 credit toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.
Release date: October 31, 2004 Expiration date: October 31, 2005
Disclosure Policy | Back to top
As a sponsor accredited by the Accreditation Council for Continuing Medical Education, Physicians’ Education Resource must ensure balance, independence, objectivity and scientific rigor in all its sponsored activities. All faculty participating in a sponsored activity are expected to disclose to the activity audience any significant financial interest or other relationship (1) with the manufacturer(s) of any commercial product(s) and (2) with any commercial supporters of the activity. (Significant financial interest or other relationships can include such things as grants or research support, employee, consultant, major stockholder, member of speaker’s bureau, etc.) The intent of this disclosure is not to prevent an author with a significant financial or other relationship from publishing an article, but rather to provide readers with information on which they can make their own judgements. It remains for the readers to determine whether the author’s interests or relationships may influence the publication with regard to exposition or conclusion.
Edward S. Kim, MD
Grant or Research Support – AstraZeneca, Aventis Oncology, Genentech BioOncology
Jeffrey Crawford, MD
Grant or Research Support – Abgenix, Amgen, AstraZeneca, Aventis, Bristol-Myers Squibb, GlaxoSmithKline, ImClone, Immunex, Lilly, Ortho Biotech, Pfizer, QLT, Inc., Schering Plough Paid Consultant – Abgenix, Amgen, AstraZeneca, Aventis, Bristol-Myers Squibb, GlaxoSmithKline, Ortho Biotech, QLT, Inc. Speaker’s Bureau – Amgen, AstraZeneca, Aventis, Bristol-Myers Squibb, GlaxoSmithKline, Lilly, Ortho Biotech
Alan B. Sandler, MD
Grant or Research Support – Amgen, AstraZeneca, Aventis, Bristol-Myers Squibb, Genentech BioOncology, Lilly, Pfizer Paid Consultant – Bristol-Myers Squibb Speaker’s Bureau – Aventis, Bristol-Myers Squibb, Lilly, Pfizer
Rajesh K. Malik, MB, ChB
Employee – EMD Pharmaceuticals (former), Adherex Technologies, Inc. (current)
The articles in this CME activity might include discussion of investigational and/or unlabeled uses of drugs. If an article includes discussion of investigational and/or unlabeled uses of a drug, specific information is located on the title page. Please refer to the full prescribing information for each drug discussed in this newsletter for FDA-approved dosing, indications, and warnings.
Cancer Conference Highlights (ISSN: 1530-1745) is
produced by Physicians’ Education Resource, Dallas, TX. An unrestricted educational grant for this publication was provided by Bristol-Myers Squibb.
Cover Illustration | Back to top
Activation of the epidermal growth factor receptor (EGFR). EGFR signal transduction pathways are activated when EGF binds to EGFR and induces receptor dimerization. The tertiary structure of the extracellular domain of EGFR in it’s monomeric, inactive state reveals that the sequences responsible for dimer formation are sequestered in an autoinhibiotry conformation in the absence of EGF (Panel A). Binding of EGF (Panel B) results in a major conformational change in the arrangement of the extracellular EGFR domains that exposes the interface for dimerization (Panel C). Dimerization of EGF-activated receptor monomers promotes autophosphorylation of the intracellular tyrosine kinase domain and activation of the downstream signal transduction cascade (Panel D).
The views and opinions expressed in this publication are those of the authors and do not necessarily reflect the views of the sponsor or publisher. Although great care has been taken in compiling and checking the information given in this publication to ensure accuracy, the authors, Bristol-Myers Squibb, and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this publication, whether arising from negligence or otherwise howsoever or for any consequences
arising therefrom.
Please consult full prescribing information for any drugs or procedures discussed within.
All rights reserved. No part of this publication may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.
©Copyright 2004 by Physicians’ Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.
All correspondence should be directed to:
Editor, Cancer Conference Highlights
Physicians’ Education Resource
3535 Worth St.
Suite 4802
Dallas, TX 75246
Phone: (214) 820-8079
Fax: (214) 820-8844
E-mail: CME@pergrouplp.com
Editorial Staff:
Publishing Manager – B. Diane Gambill, PhD
Assistant Publishing Manager – David Lee, PhD
Managing Editor – Jennifer Klem, PhD
Manager, CME and Content – Preeta Tyagi, PhD
Senior Medical Editor – Jay Delmar, PhD
Associate Medical Editor – Jill Cowherd
Medical Editor/Proofreader – Pete Sloan
Acquisitions – Anissa Mitchell
ISSN: 1530-1745
Back to top
|
